Navigation Links
ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
Date:11/9/2009

MIAMI, Nov. 9 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies. These results were presented in poster sessions at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Miami Beach, FL.

In a poster presentation titled, "Treatment of Ocular Itching with Bepotastine Besilate Ophthalmic Solution 1.5% for Subjects with More Severe Itching Response in a Conjunctival Allergen Challenge (CAC) Clinical Model of Allergic Conjunctivitis," integrated results from two Phase 3 studies demonstrated Bepreve 1.5% was as effective in suppressing ocular itching in patients with more severe itching as in patients with all grades of ocular itching. A total of 157 patients were enrolled in two 7-week, masked, randomized, placebo-controlled CAC clinical studies (1 single site, 1 multi-site). 113 patients exhibited bilateral ocular itching grades greater than or equal to 3 at screening during study visit 2. Individuals were assessed at 15 minutes, 8 hours, or 16 hours following instillation at study visits spaced 2 weeks apart during the enrollment period. The difference in mean itching grades (placebo-active) for the more severely affected subjects was within plus or minus 0.1 unit of the differences for the entire intent-to-treat (ITT) population. Authors of the poster were J. I. Williams, J. A. Gow, P. J. Gomes, M. B. Abelson, and T. R. McNamara.

ISTA presented more results from CAC clinical trials with Bepreve 1.0% and 1.5% in the following poster presentations at the same meeting:

Bepotastine Besilate Ophthalmic Solution 1.5% Reduces Nasal Congestion with Rapid Onset in a Clinical Model of Allergic Conjunctivitis

Authors: G. L. Torkildsen, J. I. Williams, J. A. Gow, P. J. Gomes, T. R. McNamara

The Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis - Does Assumption of a Normal Data Distribution Influence the Means for Evaluating Clinical and Statistical Significance?

Authors: K. S. Kennedy, J. I. Williams, J. A. Gow, M. B. Abelson, T. R. McNamara

Abstracts are published in the November issue of Annals of Allergy, Asthma & Immunology and are available online at www.annallergy.org.

About Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5%

Bepreve is a non-sedating, highly selective antagonist of the histamine (H1) receptor. It has a stabilizing effect on mast cells, and it suppresses the migration of eosinophils into inflamed tissues. The compound's primary mechanisms of action are believed to make it an effective treatment against ocular itching associated with allergic conjunctivitis.

Bepreve was approved by the U.S. Food and Drug Administration in September 2009 for the treatment of ocular itching associated with allergic conjunctivitis. Bepotastine has been approved in Japan for systemic use in the treatment of allergic rhinitis since 2000 and urticaria/pruritus since 2002. It is marketed in Japan by Mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION®. TALION was co-developed by Tanabe Seiyaku and Ube Industries, Ltd., who discovered bepotastine. In 2001, Tanabe Seiyaku granted Senju Pharmaceutical Co., Ltd., exclusive worldwide rights, with the exception of certain Asian countries, to develop, manufacture and market bepotastine for ophthalmic use. In 2006, ISTA licensed the exclusive North American rights from Senju to an eye drop formulation of bepotastine for the treatment of allergic conjunctivitis. In 2007, ISTA licensed exclusive North American rights to nasal dosage forms of bepotastine from Tanabe Seiyaku and obtained a future right to negotiate for a North American license to oral dosage forms of bepotastine for allergy treatment.

Full prescribing information for Bepreve(TM) is available on ISTA Pharmaceuticals' website at http://www.istavision.com/pdf/Bepreve_insert.pdf.

About ISTA Pharmaceuticals

ISTA Pharmaceuticals is the fourth largest branded ophthalmic pharmaceutical business in the U.S. ISTA's four marketed products plus its product candidates include therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye. The Company is developing a strong product pipeline to fuel future growth and market share, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' website at http://www.istavision.com.

Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5%, Xibrom(TM) (bromfenac ophthalmic solution) 0.09%, and Istalol® (timolol maleate ophthalmic solution) 0.5% are trademarks of ISTA Pharmaceuticals.

SOURCE ISTA Pharmaceuticals, Inc.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
2. DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
4. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
5. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
6. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Peregrine Pharmaceuticals Awarded Second Broad U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
11. VIA Pharmaceuticals Featured at American Heart Association Scientific Sessions 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... PUNE, India , February 10, 2016 ... to a new market research report "Pharmaceutical Packaging Equipment ... Packaging, Wrapping, Labeling & Serialization), by Product Type (Tablet, ... to 2020", published by MarketsandMarkets, studies the global market during ... is expected to grow at a CAGR of 6.9% ...
(Date:2/10/2016)... February 10, 2016 ... Targeted Therapeutics and Companion Diagnostic Market to 2019 ... and Environment" research report indicates that the core ... billion by 2020 growing at a CAGR of ... diagnostics and targeted therapeutics and is dominated by ...
(Date:2/9/2016)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic products for spine surgery, ... surgery and other surgical applications, today announced financial ... half of fiscal year 2016 ended December 31, ... --> Highlights for the second quarter and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The ... and inspirational speaker Jan Fox will serve as keynote speaker at the organization’s ... participants with tools to more effectively communicate with their own organizational staff and ...
(Date:2/10/2016)... West Palm Beach, Florida (PRWEB) , ... February ... ... Golf & Country Club) announced that it has been awarded the prestigious Distinguished ... of the World award program conducted by BoardRoom magazine, one of the most ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week announced the ... monitor mounts ever. , “Our goal was to develop a product from the ... that we have ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. ...
(Date:2/10/2016)... ... 2016 , ... A new leadership team for Mid-South Youth Camp, operated by ... the announcement Monday night, Feb. 8, prior to the evening session of the university’s ... creator of GO! Camp, has been named director. Gayle McDonald, currently the assistant director ...
(Date:2/10/2016)... (PRWEB) , ... February 09, 2016 , ... ... sports concussion, yet the cause of injury may be one of many possible ... advanced PT Continuing Education Course , Mastering Rehab Solutions for the ...
Breaking Medicine News(10 mins):